An official website of the United States government
Home
Name
Vonjo
Alternate Names
Pacritinib
Pacritinib citrate
Abbreviations
None
Category
Chemotherapy
Subcategory
JAK inhibitor
NSC Number
None
Primary Site
Bone marrow
Histology
Myelofibrosis
Remarks
March 1, 2022 FDA has granted accelerated approval for Vonjo (pacritinib) capsules to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/µL.
Coding
This drug should be coded
